Sophiris Bio (NASDAQ:SPHS) issued its earnings results on Wednesday. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.02), Bloomberg Earnings reports.
Sophiris Bio stock traded down $0.02 during mid-day trading on Thursday, reaching $2.14. 80,102 shares of the company’s stock were exchanged, compared to its average volume of 196,809. The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.60. Sophiris Bio has a 12 month low of $1.80 and a 12 month high of $2.95. The firm has a market capitalization of $64.44, a PE ratio of -11.89 and a beta of 1.30.
A hedge fund recently raised its stake in Sophiris Bio stock. Vanguard Group Inc. lifted its holdings in shares of Sophiris Bio Inc (NASDAQ:SPHS) by 1.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 731,437 shares of the biopharmaceutical company’s stock after acquiring an additional 7,600 shares during the period. Vanguard Group Inc. owned 2.43% of Sophiris Bio worth $1,609,000 at the end of the most recent reporting period. 6.37% of the stock is owned by institutional investors and hedge funds.
About Sophiris Bio
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.